Percutaneous Coronary Intervention (PCI) Clinical Trials

Clinical trials related to Percutaneous Coronary Intervention (PCI) Procedure

Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The REFLOW AMI Trial aims to determine whether prophylactic high-dose intracoronary adenosine reduces slow-flow or no-reflow (SNR) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Slow-flow or no-reflow occurs when blood flow to the heart muscle remains reduced despite treatment of the blocked coronary artery. This complication can lead to greater heart muscle damage and worse clinical outcomes. The study will evaluate a protocol involving 200 micrograms of intracoronary adenosine administered before each balloon or stent inflation during PPCI. Researchers will compare outcomes with standard PPCI care without prophylactic adenosine. The main questions the study aims to answer are: * Does prophylactic intracoronary adenosine reduce the incidence of slow-flow or no-reflow after PPCI? * Does the protocol improve post-PCI coronary blood flow, assessed by TIMI flow grade and myocardial blush grade? * What are the rates of major adverse cardiovascular events (MACE) during hospitalization and at 30 days? * Does the protocol affect left ventricular ejection fraction (LVEF) at discharge and at 30 days? * Does the protocol improve functional capacity at 30 days, assessed by the six-minute walk test? * Is the prophylactic adenosine protocol safe? Participants will undergo PPCI according to their assigned study group and will be assessed for angiographic outcomes, safety events, and clinical outcomes during hospitalization and follow-up, including at 30 days.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• 18 years and older of either gender

• Diagnosis of STEMI

• Undergoing primary PCI

Locations
Other Locations
Pakistan
Dow University of Health Sciences,Karachi
RECRUITING
Karachi
Punjab institute of cardiology Lahore
RECRUITING
Lahore
Contact Information
Primary
Muzaffar Ali Zahidi, MBBS,FCPS Med,FCPS Cardiology
muzcardio@gmail.com
+923004358267
Backup
Muhammad Shuaib Abid, MBBS,FCPS (Cardiology)
Shoaibabid7@hotmail.com
+923336229702
Time Frame
Start Date: 2026-08-14
Estimated Completion Date: 2027-08-14
Participants
Target number of participants: 660
Treatments
Experimental: Experimental
Intracoronary adenosine (200µg) injected in less than thirty seconds just before each balloon or stent inflation.
Other: Control
Participants receive standard treatment for ST-elevation myocardial infarction (STEMI), including primary percutaneous coronary intervention (PCI) and guideline-directed medical therapy, according to institutional protocols. No placebo is administered.
Sponsors
Leads: Prof Muzaffar Ali Zahidi

This content was sourced from clinicaltrials.gov